Topic: checkpoint inhibitors
Imfinzi already is I-O's only FDA-approved maintenance therapy in lung cancer. Friday, the AZ med hit another benchmark to stretch out that lead.
The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.
Merck already controls a big piece of the first-line non-small cell lung cancer market, and it likely just secured most of the rest.
Merck and Roche’s immunotherapies are each approved solo for certain bladder cancer patients. But for others, chemo may work better, the FDA warned.
Tecentriq has stumbled again. The I-O drug, teamed with fellow Roche med Cotellic, fell short in a colorectal cancer test against Bayer's Stivarga.
Roche’s Tecentriq-Avastin-chemo combo may have just scored a quicker trip into the first-line lung arena, where a Merck rivalry awaits.
AstraZeneca has come up short in another lung cancer trial of its immuno-oncology combo.
It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.
Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.
In February, BMS tallied a lung cancer win for its immuno-oncology combo. But one question remained: Was the win big enough to keep it competitive?